A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DLI / donor lymphocyte infusion

[Related PubMed/MEDLINE]
Total Number of Papers: 690
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DLI  (>> Co-occurring Abbreviation)
Long Form:   donor lymphocyte infusion
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319]. ---
2020 Donor Lymphocyte-Derived Natural Killer Cells Control MHC Class I-Negative Melanoma. allo-BMT, GVHD, NK
2020 Graft-versus-cancer effect and innovative approaches in the treatment of refractory solid tumors. allo-HSCT, GVL, GVT, RDICs, RIC, TIL, TRM
2020 Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. HID, MRD, MSD
2020 Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. ADCs, allo-SCT, AML, GVHD, GVL, mAbs, NK
2020 The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. CIBMTR, CML, DLIs, HCT, OS, TKI, TKIs
2020 [Analysis of Decitabine Therapeutic Effeicacy for Patients with Relapsed MDS/AML and High-Risk AML Patients after HSCT]. allo-HSCT, CR, GVHD
2019 Allo-HSCT in transplant-naive patients with Hodgkin lymphoma: a single-arm, multicenter study. allo-HSCT, CI, GVHD, HL, mCR
2019 Basiliximab treatment of severe GVHD induced by donor lymphocyte infusion with interferon-a. GVHD, IFN-a
10  2019 Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. allo-HCT, AML, GVHD, MDS
11  2019 Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. CIK, CR, HSCT
12  2019 Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. AML, GVHD, HID-SCT, MSD-SCT
13  2019 Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. ---
14  2019 Cryopreservation and thawing of hematopoietic stem cell CD34-induced apoptosis through caspase pathway activation: Key role of granulocytes. 7-AAD, CFU-GM, FLICA, HSC
15  2019 CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. GVHD, NK, NRM
16  2019 Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. GVHD, haplo-PBSCT
17  2019 Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. LAA, NR
18  2019 Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML. allo-HSCT, AML, CR, haplo-HSCT, LSC
19  2019 G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. allo-HCT, G-CSF, GVHD
20  2019 Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology. GVHD, GVT
21  2019 Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. allo-SCT, AML, CAR, CTLs, GVHD, GVL, MRD, TCR
22  2019 Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies. allo-HSCT, GVHD, RIC
23  2019 Interferon-alpha salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. IFN-alpha, MRD
24  2019 Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease. allo-HSCT, EBV, PTLD
25  2019 Pegylated interferon-2alpha invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation. GVHD, GVL, OS, PEG-IFN-alpha, PFS, SCT
26  2019 Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. AZA, CI, GVHD
27  2019 Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies. aHSCT, CR, MR
28  2019 Safety and efficacy of fresh whole blood donor lymphocyte infusion in children. GVL, HSCT
29  2019 Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia. GVHD, HCT, OS
30  2019 Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, AML, FLT3-ITD, HR, OS, PFS
31  2019 Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions. AML, HSCT
32  2019 Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies. CR, HSCT
33  2019 The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. allo-HSCT, CI, GVHD, GvT, ORR
34  2019 [Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. ---
35  2018 Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. CR, CTCL, DFS, GVL, HSCT, NRM, OS, PR
36  2018 Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. allo-HCT, AML, OS
37  2018 Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study. HSCT
38  2018 CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. allo-SCT, GVHD, MiHA
39  2018 Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. GVHD, MTX
40  2018 Donor lymphocyte infusion in myeloid disorders. MRD
41  2018 Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. allo-SCT, AYAs, GVHD, PRS, SD
42  2018 Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. AML
43  2018 Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, EBV, EBV-CTLs, GVHD, RI
44  2018 Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. GMP, GVHD, GVL, MHC
45  2018 Genetically enhanced T lymphocytes and the intensive care unit. CAR-T cells, ICU
46  2018 Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. HSCT, TKIs
47  2018 Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. CC, HSCT, MC, RHC, TM
48  2018 Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. allo-SCT, AML, EM, GVHD
49  2018 Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, AML, CR, MRD, TLS-ERG
50  2018 Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango. allo-HSCT
51  2018 Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. CI, GVHD, HCT, HLH, OS
52  2018 Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. GVHD, HCT
53  2018 Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. allo-HSCT, AML
54  2018 The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. allo-HSCT, CAR-T, MRD
55  2018 The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation. ALC, CMV, SCT
56  2018 The Phenotype and Treatment of WIP Deficiency: Literature Synopsis and Review of a Patient With Pre-transplant Serial Donor Lymphocyte Infusions to Eliminate CMV. HSCT, PID, WAS
57  2018 Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction. allo-SCT, APCs, GVHD
58  2018 [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation]. allo-HSCT, AML
59  2017 A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. allo-SCT, DC, SD
60  2017 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. CMML, HCT-CI, HSCT, IPSS-R, MDS
61  2017 Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. allo-HCT, MM
62  2017 Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations. DMSO
63  2017 Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation. aGvHD, allo-HSCT, HID, HR, MRD, PRS
64  2017 Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Chemo-DLI, GVHD, HSCT, MRD
65  2017 Copper-associated hepatitis in a patient with chronic myeloid leukemia following hematopoietic stem cell transplantation: A case report. AIHA
66  2017 CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy. ALL, CML, CTC28, GVHD, GVT
67  2017 Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells. CAR, CIK, CTL, DC, HSCT, LAA, NK
68  2017 Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance. ELISPOT, HLA, PML, VLPs
69  2017 Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program. BMT, GVHD, UDLI
70  2017 Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. allo-HCT, GVL
71  2017 Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. FDC, GVM, HSCT, MC, OS, PFS, RR
72  2017 Donor T-cell responses and disease progression patterns of multiple myeloma. allo-SCT, BM, GVM, PFS
73  2017 Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. haplo-HCT, LOC, PB, PTCy
74  2017 Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL. ---
75  2017 Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. DCs, GVT, mHags, MM
76  2017 Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. AL, HR, MDS, NRM, OS, SCT, TCD
77  2017 Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. AML, Aza, GVL, MDS, mRNA, t-MDS, WT1
78  2017 Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. MSDT, pre-MRD
79  2017 Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies. GVHD, GVT, HSCT, PBMCs
80  2017 Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15. ADCC, NK, PBSCs
81  2017 New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity. GVT, IL-15, IL-15SA
82  2017 Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature. allo-HSCT, PGF
83  2017 Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the societe Francophone de greffe de moelle et de therapie cellulaire (SFGM-TC). AL, HR, SCT, SFGM-TC
84  2017 Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. aGVHD, cGVHD, CIK
85  2017 Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. AL, allo-HSCT, MRD, PCR
86  2017 Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia. allo-HSCT, GRFS, GVHD
87  2017 Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. allo-HSCT, GVHD, MRD
88  2017 Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies. HSCT, MC
89  2017 Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. GVHD, GVL, MiHAs
90  2017 Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. allo-SCT, AML, AZA
91  2017 Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review. ASCT, TKIs
92  2017 Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT. GVHD, GVL, HSCT
93  2017 [Successful treatment of secondary graft failure with donor lymphocyte infusion in a post-allogeneic stem cell transplant acute myeloid leukemia patient]. BMT
94  2016 Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches. AL, allo-HSCT, AML, CARs, CR, GVHD, OS
95  2016 Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. allo-SCT, ASCT, RIC, TRM
96  2016 Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group. allo-HSCT, CI
97  2016 Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. allo-SCT, BV, HL
98  2016 Chemotherapy versus Hypomethylating Agents fortheTreatment of Relapsed Acute Myeloid Leukemia andMyelodysplastic Syndrome after Allogeneic StemCellTransplant. allo-SCT, AML, CR, HAs, MDS, ORR, OS, PFS
99  2016 Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. B-ALL, CAR, CIK, IFN, IL-15, IL-2, MHC, NK
100  2016 Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases. GF, HSCT, MC